Seelig H P, Appelhans H, Bauer O, Blüthner M, Hartung K, Schranz P, Schultze D, Seelig Claudia A, Volkmann M
Medizinisches Versorgungszentrum Labor Prof. Seelig, Karlsruhe, Germany.
Clin Lab. 2011;57(9-10):753-65.
Indirect immunofluorescence (IIFT) on in house HEp-2 cell preparations revealed a novel antibody giving a granular cytoplasmic pattern not described before, which on two commercial cell preparations revealed a "rings and rods" pattern. This pattern was also observed in four HCV-RNA carriers and prompted the identification of the reactive antigen and the evaluation of the antibody prevalence in HCV-RNA carriers and control groups.
The antigen's molecular weight was determined by radioimmunoprecipitation of 35S-methionine labeled cell proteins. Expression library screening and sequencing was performed by standard techniques using an oligo(dT)-primed human HeLa cell cDNA expression library. Antibodies against the novel antigen Inositol-5'-monophosphatdehydrogenase 2 (IMPDH2) were analyzed by IIFT, western blot, line blot, and radioimmunoprecipitation assay (RIPA). IIFT was performed on commercial HEp-2 cells and cells cultivated in house for 24 - 60 hours, with or without the IMPDH2 inhibitors mycophenolic acid (MPA) or ribavirin, and subjected to various fixation conditions. Western and line blots were performed with IMPDH2 synthesized in E. coli, RIPA with 35S-methionine-IMPDH2 from in vitro transcription/translation products. Sera screened were positive for HCV-RNA (108), HBV-DNA (100), anti-mitochondrial (31), anti-actin (42), and anti-nuclear antibodies (51) and negative for HCV-RNA (100) and blood donors (100).
IMPDH2 is capable of considerable intracellular rearrangements (upon action of inhibitors like MPA and ribavirin), which explains the contrasting immunofluorescence patterns in cells from different sources. By RIPA, proven to be the sole assay suitable for screening of anti-IMPDH2 in human sera, autoantibodies were found in 35.2% of HCV-RNA carriers and in low concentrations in 31% of anti-actin positive patients suspicious of autoimmune hepatitis. Antibodies reacted preferentially with conformational epitopes. Compared to the low concentration of anti-IMPDH2 found in other disease groups, high antibody concentrations were observed in HCV-RNA carriers.
The common occurrence of anti-IMPDH2 in HCV-RNA carriers may be related to ribavirin therapy, causing intracellular aggregation of IMPDH2 thereby altering its immunogenicity. In this study the "rods and rings" immunofluorescence pattern observed could be ascribed to anti-IMPDH2. Anti-IMPDH2 may cause difficulties in interpretation of immunofluorescence patterns in routine autoantibody testing.
对自制的人喉表皮癌细胞(HEp-2)细胞制剂进行间接免疫荧光检测(IIFT)时,发现一种新型抗体呈现出之前未描述过的颗粒状细胞质模式,而在两种商业细胞制剂上则呈现出“环和棒”模式。在4例丙型肝炎病毒核糖核酸(HCV-RNA)携带者中也观察到了这种模式,这促使对反应性抗原进行鉴定,并评估HCV-RNA携带者和对照组中该抗体的流行情况。
通过对35S-甲硫氨酸标记的细胞蛋白进行放射免疫沉淀来确定抗原的分子量。使用寡聚(dT)引物的人宫颈癌细胞(HeLa)细胞cDNA表达文库,通过标准技术进行表达文库筛选和测序。通过IIFT、蛋白质免疫印迹法(western blot)、线性免疫印迹法(line blot)和放射免疫沉淀测定法(RIPA)分析针对新型抗原肌醇-5'-单磷酸脱氢酶2(IMPDH2)的抗体。IIFT在商业HEp-2细胞以及自制培养24 - 60小时的细胞上进行,添加或不添加IMPDH2抑制剂霉酚酸(MPA)或利巴韦林,并采用各种固定条件。蛋白质免疫印迹法和线性免疫印迹法使用在大肠杆菌中合成的IMPDH2进行,RIPA使用来自体外转录/翻译产物的35S-甲硫氨酸-IMPDH2进行。所筛选的血清中,丙型肝炎病毒核糖核酸(108例)、乙型肝炎病毒脱氧核糖核酸(100例)、抗线粒体抗体(31例)、抗肌动蛋白抗体(42例)和抗核抗体(51例)检测呈阳性,丙型肝炎病毒核糖核酸(100例)和献血者(100例)检测呈阴性。
IMPDH2能够发生显著的细胞内重排(在MPA和利巴韦林等抑制剂作用下),这解释了不同来源细胞中免疫荧光模式的差异。通过RIPA(被证明是唯一适用于筛查人血清中抗IMPDH2抗体 的检测方法)发现,35.2%的HCV-RNA携带者中存在自身抗体,在31%疑似自身免疫性肝炎的抗肌动蛋白阳性患者中抗体浓度较低。抗体优先与构象表位发生反应性。与其他疾病组中发现的低浓度抗IMPDH2相比,HCV-RNA携带者中观察到高抗体浓度。
HCV-RNA携带者中抗IMPDH2抗体的普遍存在可能与利巴韦林治疗有关,导致IMPDH2在细胞内聚集,从而改变其免疫原性。在本研究中,观察到的“棒和环”免疫荧光模式可能归因于抗IMPDH2。抗IMPDH2可能会在常规自身抗体检测中对免疫荧光模式的解读造成困难。